Apellis Pharmaceuticals Acquired by Biogen | Healthcare M&A Deal

Biogen has completed the acquisition of Apellis Pharmaceuticals, a pharmacy business in Delaware, for $41.00 per share plus up to $4.00 in contingent value rights. Apellis Pharmaceuticals develops treatments in the healthcare sector, and Biogen acquisitions aim to expand its pipeline and commercial capabilities in pharmacy. The merger acquisition is structured through Aspen Purchaser Sub, a wholly owned subsidiary of Biogen, and is filed as a Schedule TO tender offer for all outstanding Apellis common stock. The strategic acquisition is a strategic acquisition by a strategic buyer, with consideration totaling about $1 million in the disclosed filing and an announced status for healthcare M&A.